[Comment] Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer

The use of systemic therapy for patients with stage IIIB or IV non-small-cell lung cancer has, in general, evolved rapidly over the past two decades. However, somewhat paradoxically, in 2023, for most patients with non-oncogene-addicted, relapsed non-small-cell lung cancer, treatment options have changed little since the introduction of docetaxel around the turn of the century.